X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
NBI-921352, an investigational, selective sodium channel 1.6 inhibitor (Nav1.6) currently under development in adult patients with focal onset seizures (FOS), failed to demonstrate meaningful reduction in seizure frequency.
Lead Product(s): NBI-921352
Therapeutic Area: Rare Diseases and Disorders Product Name: NBI-921352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xenon Pharmaceuticals Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
NBI-921352 is an investigational, selective sodium channel 1.6 inhibitor (Nav1.6) currently under development for the potential treatment of SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) in children and adults.
Lead Product(s): NBI-921352
Therapeutic Area: Neurology Product Name: NBI-921352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
Xenon has an ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a selective Nav1.6 sodium channel inhibitor.
Lead Product(s): NBI-921352
Therapeutic Area: Neurology Product Name: NBI-921352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $15.0 million Upfront Cash: $6.7 million
Deal Type: Collaboration January 12, 2022
Details:
Xenon ongoing collaboration with Neurocrine Biosciences to develop treatments including XEN901, now known as NBI-921352 a clinical stage selective Nav1.6 sodium channel inhibitor with potential in SCN8A developmental and epileptic encephalopathy and other forms of epilepsy.
Lead Product(s): NBI-921352
Therapeutic Area: Neurology Product Name: NBI-921352
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $1,775.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration September 08, 2021
Details:
U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients.
Lead Product(s): NBI-921352
Therapeutic Area: Neurology Product Name: XEN901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xenon Pharmaceuticals Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
